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for measurement error that should be exceeded in or-
der to represent a real difference in a patient’s clinical 
condition.
The aim of the present study was to investigate 
the relative and absolute reliability of the 2MWT 
and 6MWT in patients with NMD. The walk tests in 
some of the patients have been published previously 
in Andersen et al. (5).
METHODS
Recruitment
A total of 93 patients were recruited from March 2014 to January 
2015. Patients followed at the Copenhagen Neuromuscular 
Center were invited to participate in the study. Inclusion criteria 
were: biopsy or genetically confirmed NMD; age ≥ 18 years; 
and capacity to walk further than 60 m. Exclusion criteria were: 
conditions with a significant impact on walking capacity. 
Study design
This is a methodological study. The patients were tested at our 
Neuromuscular Center on 2 test days at the same time of the 
day, 1–2 weeks apart. On each test day, a 2MWT and a 6MWT 
were performed, with 30 min rest between tests. Patients were 
block randomized (block size 10) using sealed envelopes on the 
first test day to perform either the 2MWT or the 6MWT first. 
The same order was used for re-test. The 6MWT was performed 
according to the American Thoracic Society (ATS) guidelines 
(6) and the 2MWT was a modified version of the ATS guidelines 
for the 6MWT. In the 2MWT, patients were informed that the 
test was a 2MWT, and the encouragement used at 3 min in ATS 
guidelines was used at 1 min in the 2MWT. Two investigators 
performed the 2MWT and 6MWT, but each patient was instruc-
ted by the same investigator at test and re-test. 
Patient characteristics and walking distance in the present 
study investigating relative and absolute reliability have been 
reported in a published study assessing validity of the 2MWT 
compared with the 6MWT (5). The Regional Committee on 
Health Research Ethics in Denmark approved the study (H-4-
2014-FSP) and informed verbal consent was obtained.
Statistical analysis
Analyses have been conducted in SPSS version 22, except 
Student’s paired t-tests, which were performed in Microsoft 
Excel 2010. As subgroup behave differently, we have con-
ducted both analyses for all patients as a group and for each 
NMD. Data for all patients as a group and for each subgroup 
were normally distributed tested by Shapiro-Wilk test and 
Quantile-Quantile Plot in SPSS. Systematic differences in 
walking distance between test and re-test were tested by the 
parametric 2-sided Student’s paired t-test. Patient characteristics 
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Objective: The 2- and 6-minute walk tests are used 
to evaluate walking capacity, but reliability has been 
sparsely investigated in patients with neuromuscu-
lar diseases. The aim of this study was to investiga-
te the relative and absolute reliability of the 2- and 
6-minute walk tests in patients with neuromuscular 
diseases.
Design: Each patient performed a 2- and a 6-minute 
walk test on 2 test days separated by 1–2 weeks.
Subjects: A total of 93 adult patients (mean age 53 
years, age range 22–83 years) with 12 different neu-
romuscular diseases were included. 
Results: The mean walking distance increased by 4.3 
and 11.2 m (p < 0.001) in repeated 2- and 6-minute 
walk tests, respectively. Intraclass correlation coef-
ficient in the 2- and 6-minute walk tests was 0.99 
(p < 0.001). Standard error of measurement was 4.9 
m in the 2-minute walk test and 14.0 m in the 6-mi-
nute walk test. Minimal detectable difference was 
13.7 m in the 2-minute walk test and 38.8 m in the 
6-minute walk test. 
Conclusion: These findings show good relative relia-
bility of the 2- and 6-minute walk tests in patients 
with neuromuscular diseases. However, absolute re-
liability demonstrated variability in neuromuscular 
diseases. This should be considered when interpre-
ting a change in walking distance.
Key words: neuromuscular diseases; reproducibility of re-
sults; walk test.
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The 2-minute walk test (2MWT) and 6-minute walk test (6MWT) are used to evaluate walking capacity 
in patients with neuromuscular diseases (NMD) in 
the clinic and in clinical trials. However, reliability of 
the 2MWT has been documented only in Duchenne 
muscular dystrophy (1) and reliability of the 6MWT 
has been documented only in Duchenne muscular 
dystrophy (1, 2), myotonic dystrophy (3), and spinal 
and bulbar muscular atrophy (4). Relative reliability 
characterizes the trustworthiness of a test in a specific 
diagnosis. Absolute reliability provides actual values 
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3632MWT and 6MWT reliability in neuromuscular diseases
calculation with alpha level = 0.05, 2-tailed test and correlation 
coefficient = 0.90 required a sample of 7 patients (7). 
RESULTS 
Patient characteristics 
Patient characteristics were as follows: 12 different 
NMD (Fig. 1, Table I), 32 females, 61 males, age 53 
years (SD 17), height 1.74 m (SD 0.10), weight 76.2 kg 
(SD 16.3), body mass index 25.2 kg/m2 (SD 5). Mean 
muscle strength, using the Medical Research Council 
scale, for ankle dorsal flexion was 4 (SD 1.6), ankle 
plantar flexion 4.4 (SD 1.1), hip flexion 4.4 (SD 1), and 
hip extension 4.5 (SD 0.7). Twenty-eight patients used 
assistive devices in the 2MWT and 6MWT. At re-test 
of the 2MWT, 60 patients walked longer, 27 walked 
shorter, and 6 walked the same distance. Similarly, in 
the 6MWT, 67 patients walked longer at re-test, 24 
walked shorter, and 2 walked the same distance. 
and change in walking distance between tests are presented 
as mean and standard deviation (SD). Relative reliability was 
determined by intraclass correlation (ICC) coefficient (model: 
3, 2-way mixed, type: absolute agreement, confidence interval: 
95%). Relative reliability indicates the degree of reliability and 
ranges from 0.00 = no reliability to 1.00 = perfect reliability (7). 
The higher reliability, the less measurement error in the assess-
ment. Absolute reliability was investigated by standard error of 
measurement (SEM), minimal detectable difference (MDD) 
(repeatability) for 95% confidence interval and by Bland-Altman 
plots, which also tested for heteroscedasticity (if variability is 
unequal across magnitudes of the mean). 
SEM = SD*√1-ICC (7)  MDD95 = 1.96*SEM * √2 (7)
SEM% and MDD% were calculated using the formulas: 
SEM% = SEM/mean*100 (8) MDD95% = MDD/mean*100 (8)
The mean for SEM and MDD95 is for the test and re-test. SEM 
and MDD95 estimate the smallest change that is beyond measu-
rement error in a group and in a single subject, respectively (3). 
Bland-Altman plot visualizes agreement between repeated tests. 
The higher reliability, the closer the dots are to zero. Statistical 
significance was set at p ≤ 0.05. Results are shown for the NMD 
patients all together and for each NMD. Post hoc sample size 
Fig. 1. Walking distance in the 2MWT and 6MWT in individual patients with neuromuscular diseases. 2MWT: 2-minute walk test; 6MWT: 6-minute walk test; 
DM1: myotonic dystrophy type 1; LGMD: limb-girdle muscular dystrophy; SBMA: spinobulbar muscular atrophy/Kennedy disease; CMT: Charcot-Marie-Tooth 
disease/hereditary motor and sensory neuropathy; FSHD1: facioscapulohumeral muscular dystrophy type 1; MM: mitochondrial myopathy; IBM: sporadic 
inclusion body myositis; BMD: Becker muscular dystrophy. The walking distance (m) is on the y-axis and test days on the x-axis. 
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364 K. L. Knak et al.
Agreement between repeated 2MWT and 6MWT is 
shown in Bland-Altman plots (Fig. 2, A + B) with a 
95% CI showing a variation of –13.9 to + 22.5 m for 
the 2MWT and –40.8 to + 63.3 m for the 6MWT. The 
difference in walking distance from test to re-test was 
not dependent on walking distance on the first test day, 
meaning there was no heteroscedasticity. 
DISCUSSION
The main finding of the present study is that the 2MWT 
and 6MWT are as reliable in NMD as in other diseases. 
Relative reliability was excellent, with an ICC of 0.99 
in both the 2MWT and 6MWT. Similar results were 
seen in all subgroups (ICC > 0.90). These findings are 
consistent with previous studies of the 2MWT and 
6MWT in different neuromuscular (3, 4, 9, 10) and 
non-neuromuscular (11) conditions (ICC 0.61–1.00). 
Relative and absolute reliability
For all patients as a group the mean walking distance in 
repeated 2MWT increased by 4.3 m (SD 9.1) (2.9 %) 
from 144.9 (SD 51.8) to 149.2 m (SD 52.2) (p < 0.001) 
and in the 6MWT by 11.2 m (SD 26.0) (2.7 %) from 
412.0 (SD 155.6) to 423.2 m (SD 158.1) (p < 0.001). 
Results for subgroups are shown in Fig. 1.
Relative reliability was high for all patients as a 
group in 2MWT and 6MWT (ICC = 0.99, p < 0.001, 
95% CI 0.98–1.00). Similar results were seen in all 
subgroups (ICC > 0.90, p < 0.004). For all diseases as a 
group SEM and MDD95 were 4.9 m (3.4%) and 13.7 m 
(9.3%), respectively, in the 2MWT, and 14.0 m (3.4%) 
and 38.8 m (9.3%) in the 6MWT. In subgroups, SEM 
varied from 0.5–9.1 m in the 2MWT and 7.1–37.0 m 
in the 6MWT, and MDD95 varied between 1.5–25.2 
m in the 2MWT and between 19.7–102.5 m in the 
6MWT. Results for subgroups are shown in Table II. 
Table I. Walking distance in the 2-minute walk test and 6-minute walk test in each neuromuscular diseases
2MWT 6MWT
n
Day 1
Mean (SD)
Day 2
Mean (SD)
Difference
Mean (SD) p-value
Day 1
Mean (SD)
Day 2
Mean (SD)
Difference
Mean (SD) p-value
DM1 15 180.4 (52.0) 194.4 (56.5) 14.0 (9.2) 0.02* 524.5 (158.7) 528.6 (169.3) 4.1 (30.6) 0.61 
LGMD 14 130.0 (56.6) 130.5 (55.0) 0.5 (5.0) 0.71 371.7 (164.1) 377.6 (160.4) 5.9 (15.5) 0.18 
SBMA 13 125.8 (44.8) 125.6 (42.5) –0.2 (18.7) 0.98 341.5 (131.6) 355.5 (127.1) 14.0 (23.3) 0.05*
CMT 12 149.9 (24.4) 148.8 (27.9) –1.2 (13.1) 0.76 423.8 (62.8) 435.3 (74.3) 11.5 (23.9) 0.12
FSHD1 11 161.1  (56.4) 163.8 (53.4) 2.7 (8.2) 0.30 460.0 (169.0) 474.1 (164.7) 14.1 (25.5) 0.10
MM 9 141.9 (61.9) 148.7 (66.3) 6.8 (9.7) 0.07 393.8 (196.2) 411.3 (219.2) 17.6 (36.4) 0.19
IBM 8 104.8 (24.7) 109.5 (27.4) 4.8 (13.9) 0.36 292.5 (68.4) 306.0 (71.3) 13.5 (39.4) 0.36 
BMD 5 156.4  (52.0) 165.8 (40.3) 9.4 (16.5) 0.27 467.6 (137.1) 483.8 (125.1) 16.2 (21.8) 0.17
*p ≤ 0.05.
2MWT: 2-minute walk test; 6MWT: 6-minute walk test; DM1: myotonic dystrophy type 1; LGMD: limb-girdle muscular dystrophy; SBMA: spinobulbar muscular 
atrophy/Kennedy disease; CMT: Charcot-Marie-Tooth disease/hereditary motor and sensory neuropathy; FSHD1: facioscapulohumeral muscular dystrophy type 
1; MM: mitochondrial myopathy; IBM: sporadic inclusion body myositis; BMD: Becker muscular dystrophy.
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Fig. 2. Absolute reliability of the 2MWT and 6MWT in patients with neuromuscular diseases. 2MWT: 2-minute walk test, 6MWT: 6-minute walk test. 
The different NMD are symbolized by different colours. Each dot represents a single patient. Various (6): spinal muscular atrophy (3), myotonia 
congenital Thomsen disease (1), congenital myopathy (1) and polymyositis (1). A + B: The Bland-Altman plots show the change in walking distance 
between repeated tests for each patient compared with mean ± 1.96 standard deviation (SD) for all NMD as a group. The walking distance on test 
day 1 indicates whether the variability among tests depends on the walking distance on the first test day. Therefore, data on the x-axis is the walking 
distance from the first test day and not the mean walking distance from test day 1 and test day 2. The x-axis shows the walking distance (m) on 
the first test day. The y-axis shows the change in walking distance (m) from the first test day to the second test day. The closer the dots are to 
zero the more reliable the test is. The 3 horizontal lines in each graph illustrate the mean difference from test to re-test and the 95% confidence 
intervals, with the upper line showing 1.96*SD plus the mean and the lower line showing 1.96*SD minus mean.
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A general guideline suggests that ICC > 0.75 = good 
reliability, and ICC > 0.90 is recommended for clini-
cal decisions (7). According to these guidelines, the 
2MWT and 6MWT are reliable measures for clinical 
decisions. However, the acceptable level of ICC de-
pends on the specific circumstances. A lower level of 
ICC can be accepted if 2MWT or 6MWT are secondary 
endpoints as opposed to a primary outcome. 
Despite the good relative reliability of the 2MWT 
and 6MWT, there was a statistically significant in-
crease in walking distance from test to re-test of 3% 
in both tests for NMD as a group (4.3 and 11.2 m in 
the 2MWT and 6MWT, respectively), which could be 
due to a learning effect. Variation was also present in 
subgroups, but the variation was not statistically signi-
ficant in most of them. The results might be explained 
by small samples in subgroups and the large variability 
in walking capacity within subgroups. Statistically 
significant variability in walking distance in repeated 
6MWT has been reported in previous studies of NMD 
with an increase of 3–5% (17.0–24.0 m) (3, 12). Howe-
ver, variability in post-polio syndrome (PPS) showed a 
non-statistically significant increase in walked distance 
of less than 2% in 6MWT (9) and 2MWT (10).
Absolute reliability provides information about 
absolute difference between repeated tests. In line 
with previous findings (3, 13, 14), SEM in our study 
was 4.9 m (3.4%) in the 2MWT and 14.0 m (3.4%) 
in the 6MWT for all patients as a group, but varied in 
subgroups. MDD95 was 13.7 m (9.3%) in the 2MWT 
and 38.8 m (9.3%) in the 6MWT for all patients as a 
group, but large subgroup variability was found. The 
MDD95 for the 2MWT and 6MWT is consistent with 
previous studies (3, 9, 13, 14), except from Stolwijk-
Swüste et al (10), which reported a smallest detectable 
change of 22.9 m (16.8%) for the 2MWT in PPS. The 
inconsistency might be due to different NMD and 
patient characteristics (e.g. age and functional level) 
across studies. The larger SEM and MDD95 in the 
subgroups might be explained by: (i) different NMD; 
(ii) different circumstances in repeated tests in some 
patients (e.g. poor sleep); (iii) difference in sample size 
as a larger sample reduces SEM; and (iv) difference 
in walking capacity across subgroups as there was 
a tendency that subgroups with the longest walking 
distance (myotonic dystrophy type 1 and facioscapu-
lohumeral muscular dystrophy) showed the smallest 
measurement error, while, in contrast, subgroups with 
the shortest walking distance (sporadic inclusion body 
myositis and spinobulbar muscular atrophy) showed 
the largest measurement error. Thus, measurement 
error seems to be dependent on the functional level; 
measurement error increases with decreasing walking 
capacity. Clinicians need to consider the walking 
capacity when interpreting a change between assess-
ments. SEM% and MDD95% vary between 2MWT 
and 6MWT in subgroups. Not surprisingly, those 
showing the highest SEM% in 2MWT also have the 
highest MDD95% in the 2MWT. The NMD affected in 
the peripheral nervous system (spinobulbar muscular 
atrophy and Charcot-Marie-Tooth disease) show the 
highest SEM% and MDD95% in the 2MWT. In contrast, 
most of the muscular dystrophies (myotonic dystrophy 
type 1, facioscapulohumeral muscular dystrophy and 
Becker muscular dystrophy) show the highest SEM% 
and MDD95% in the 6MWT. These findings have im-
portant implications for the interpretation of a change 
in walking distance in repeated 2MWT and 6MWT at 
follow-up or in clinical trials. The variability among 
test results, especially in outliers, could potentially 
be corrected by measuring mean heart rate during 
walking, as suggested recently (12). 
The present study was limited by only a very few 
protocol violations, such as testing performed on dif-
ferent times of day in a few patients. However, the 
patients with protocol violations showed similar results 
as the other patients and were therefore not excluded 
from the study.
Table II. Reliability of the 2MWT and 6MWT in each neuromuscular diseases
2MWT 6MWT
n
ICC
Mean (95% CI) 
SEM
Frequency (%)
MDD95
Frequency (%)
ICC
Mean (95% CI)
SEM
Frequency (%)
MDD95
Frequency (%)
DM1 15 0.99* (0.96–1.00) 0.5 (0.3) 1.5 (0.8) 0.99* (0.98–1.00) 14.4 (2.7) 40.0 (7.6)
LGMD 14 1.00* (0.99–1.00) 2.5 (1.9) 6.8 (5.2) 1.00* (0.99–1.00) 7.1 (1.9) 19.7 (5.3)
SBMA 13 0.96* (0.85–0.99) 9.1 (7.2) 25.2 (20.0) 0.99* (0.96–1.00) 13.3 (3.8) 36.9 (10.6)
CMT 12 0.94* (0.79–0.98) 6.4 (4.3) 17.7 (11.8) 0.97* (0.87–1.00) 12.6 (2.9) 35.0 (8.2)
FSHD1 11 0.99* (0.98–1.00) 4.2 (2.6) 11.5 (7.1) 0.99* (0.97–1.00) 13.6 (2.9) 37.8 (8.1)
MM 9 0.99* (0.95–1.00) 5.6 (0.7) 15.5 (10.6) 0.99* (0.96–1.00) 19.2 (4.8) 53.1 (13.2)
IBM 8 0.93* (0.66–0.99) 6.9 (6.5) 19.2 (18.0) 0.91* (0.61–0.98) 19.9 (6.6) 55.1 (18.4)
BMD 5 0.96* (0.73–1.00) 8.4 (5.2) 23.2 (14.4) 0.91* (0.91–1.00) 37.0 (7.8) 102.5 (21.6)
*p < 0.05. 2MWT: 2-minute walk test. 
6MWT: 6-minute walk test; DM1: myotonic dystrophy type 1; LGMD: limb-girdle muscular dystrophy; SBMA: spinobulbar muscular atrophy/Kennedy disease; CMT: 
Charcot-Marie-Tooth disease/hereditary motor and sensory neuropathy; FSHD1: facioscapulohumeral muscular dystrophy type 1; MM: mitochondrial myopathy; 
IBM: sporadic inclusion body myositis; BMD: Becker muscular dystrophy; ICC: intraclass correlation coefficient. SEM: standard error of measurement; MDD95: 
minimal detectable difference for 95 % confidence interval. 
J Rehabil Med 49, 2017
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In conclusion, our findings show good relative 
reliability of the 2MWT and 6MWT in patients with 
NMD as a group and in subgroups. However, absolute 
reliability demonstrated variability in NMD as a group 
and a considerable amount of variability across sub-
groups. Decreased level of walking capacity showed 
increased level of absolute measurement error. Thus, 
clinicians must be aware of the issues associated with 
absolute reliability when interpreting results of 2MWT 
and 6MWT in individual patients in the clinic. 
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